Özet:

The heat shock protein 90 (ISP90) is ATP-dependent molecular shapers and is necessary for the conformation and stabilization of a large number of important proteins responsible for the performance of cell functions. In this study, our goal is to investigate the synergistic effects of the inhibitor IASP90, the use of chemotherapeutic agents gemsitabin and sisplatin alone and/or combinations of them on the apoptotic pathway in the human cervical cancer cell line T24. The anti-tumor effects on Gemsitabin (0-500 nM) and Sisplatin (0-10 μM) alone and/or together on T24 cells were determined by the WST-1 test. Variations in individual and/or combined use of the medications prescribed with 1 μM dolanamine and variations in protein expression levels of the Bax and Bcl2 genes were determined by the western blot method. The proapoptotic gene Bax protein expression increases in translational levels, while the proapoptotic gene Bcl2 protein levels have not been significantly changed, while the proapoptotic gene Bcl2 protein levels have not increased in translational levels, while the proapoptotic gene Bcl2 protein levels have not increased in translational levels. However, the triple combination (geldanamine, sisplatin, and gemsitabine) has led to a significant decrease in the Bcl2 protein levels, while the Bax protein levels are increased compared to control. The use of a triple combination of Geldanamine, Gemsitabine and Sisplatin has led to an increase in the apoptotic activity of chemotherapists. The combined use of IPS90 inhibitors and chemotherapies can be a hopeful treatment option for the treatment of cervical cancer.

Anahtar Kelimeler: